TELESTA THERAPEUTICS INC T.TST

RS THOUGHTS !!

[blartar]

How important is it to " MANAGEMENT " to get the RS done before the Nov.18 Ad comm. decision is reported, if that's what they want.

Is our SP being held back till after the RS is done & the Adcomm report is issued ?
What difference does it make if any ?
Who will benefit the most from a RS ? ( option holders can't lose, they"ll  just re-issue new ones )
I still get the feeling that SOMEBODY is trying to squeese out the little SH.

I'm O.K. with a RS and a NASDAQ listing, but not until after the FDA decision is handed down in Feb/16.  JMHO & GLTAL

[cowdoc447]

Blartar - I totally agree. What is the downside ? So it takes a couple more months to get on NASD. Who cares - it will give us S/H who have supported this Company for ever and a day a chance to get out or hang on.

[Frogger2]

They won't even consider a R/S until after a thumbs up ADCOM. The SP is not being held down, we still don't have volume, we have small retail investors. A positive ADCOM and everything changes

[HighteawithIntrepid]

The vote for the reverse split is at the AGM on November the 12th with the AdCom meeting 6 days later on the 18th. Surely to God only an idiot would contimplate a RS before the 19th. And I dont think the new management team are idiots. Looking forward to the day we have sales. HT

[DryBones]

Look,  I think they have already concluded it won't fly with AdComm or the FDA.  So they have put in place a strategy to move forward despite that.  That it screws all us bag holders doesnt matter to them.  I don't doubt they already have the next phase 3 planned.  After rejection the FDA will tell them what they can do next.  Meanwhile kiss your dreams about

[DamnYankees]

I disagree. I think it is reasonable to assume that MCNA's throat would have been slit well before Priority Review if the ultimate intent was not to approve on Phase 3 A. Absolutely no political or financial reason to string a backwater biotech like Telesta along.  There is no serious pharma sponsoring them, no major partner promoting them, not a single relevant financier backing them and

[DryBones]

Damn.   The Boffins at the FDA don't give a fig about the company, the  size of the company or whether it is a large success story or a micro cap, or Canadian..  At least they shouldn't. Their work is to review drug submissions and methods of production. It is supposed to be impartial, objective, even scientific..   A company's  objective is to get a review

[cheetio]

By god DryBones ....ume dead on.....cheers

[cheetio]

How important is it to " MANAGEMENT " to get the RS done before the Nov.18 ........Can't make a fckin asssss out of Degeeter Ladenburg Thalmann by equity analyst Kevin Degeeter. The 12-month target price is $1 (Canadian) per share. GLTALs rate and reply